Immune-related adverse events with immune checkpoint blockade: a comprehensive review
2016 · European Journal of Cancer · 2,084 citations
https://doi.org/10.1016/j.ejca.2015.11.016
A
Anas Gazzah
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
355
Papers
7.9K
Citations
34
h-index
77
i10-index
Anas Gazzah is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Cancer Genomics and Diagnostics & Cancer Immunotherapy and Biomarkers. The author has an h-index of 34, co-authored 302 publications.
ORCID: 0000-0002-6866-6787Papers by this author
worksDabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial
2023 · Nature Medicine · 268 citations
https://doi.org/10.1038/s41591-023-02321-8
Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study
2022 · Annals of Oncology · 74 citations
https://doi.org/10.1016/j.annonc.2021.12.012
Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers
2022 · Journal of Experimental & Clinical Cancer Research · 26 citations
https://doi.org/10.1186/s13046-022-02423-0
Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report
2020 · JTO Clinical and Research Reports · 21 citations
https://doi.org/10.1016/j.jtocrr.2020.100023
Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours
2015 · British Journal of Cancer · 18 citations
https://doi.org/10.1038/bjc.2015.374
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat